| BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting N Dagan, N Barda, E Kepten, O Miron, S Perchik, MA Katz, MA Hernán, ... New England Journal of Medicine 384 (15), 1412-1423, 2021 | 2849 | 2021 |
| Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting N Barda, N Dagan, Y Ben-Shlomo, E Kepten, J Waxman, R Ohana, ... New England Journal of Medicine, 2021 | 1071 | 2021 |
| Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch, IS Kohane, BY Reis, ... The Lancet 398 (10316), 2093-2100, 2021 | 957 | 2021 |
| Myocarditis after Covid-19 vaccination in a large health care organization G Witberg, N Barda, S Hoss, I Richter, M Wiessman, Y Aviv, T Grinberg, ... New England Journal of Medicine 385 (23), 2132-2139, 2021 | 682 | 2021 |
| Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy N Dagan, N Barda, T Biron-Shental, M Makov-Assif, C Key, IS Kohane, ... Nature medicine 27 (10), 1693-1695, 2021 | 339 | 2021 |
| Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge R Arbel, Y Wolff Sagy, M Hoshen, E Battat, G Lavie, R Sergienko, M Friger, ... New England Journal of Medicine 387 (9), 790-798, 2022 | 329 | 2022 |
| Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting O Magen, JG Waxman, M Makov-Assif, R Vered, D Dicker, MA Hernán, ... New England Journal of Medicine 386 (17), 1603-1614, 2022 | 290 | 2022 |
| Developing a COVID-19 mortality risk prediction model when individual-level data are not available N Barda, D Riesel, A Akriv, J Levy, U Finkel, G Yona, D Greenfeld, ... Nature communications 11 (1), 4439, 2020 | 152 | 2020 |
| External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort … N Dagan, C Cohen-Stavi, M Leventer-Roberts, RD Balicer Bmj 356, 2017 | 117 | 2017 |
| Effectiveness of BNT162b2 vaccine against delta variant in adolescents BY Reis, N Barda, M Leshchinsky, E Kepten, MA Hernán, M Lipsitch, ... New England Journal of Medicine 385 (22), 2101-2103, 2021 | 109 | 2021 |
| Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported … B Heidecker, N Dagan, R Balicer, U Eriksson, G Rosano, A Coats, ... European journal of heart failure 24 (11), 2000-2018, 2022 | 107 | 2022 |
| BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age CJ Cohen-Stavi, O Magen, N Barda, S Yaron, A Peretz, D Netzer, ... New England Journal of Medicine 387 (3), 227-236, 2022 | 99 | 2022 |
| Automated opportunistic osteoporotic fracture risk assessment using computed tomography scans to aid in FRAX underutilization N Dagan, E Elnekave, N Barda, O Bregman-Amitai, A Bar, M Orlovsky, ... Nature medicine 26 (1), 77-82, 2020 | 90 | 2020 |
| Surgical site infections following craniotomy focusing on possible post-operative acquisition of infection: prospective cohort study O Sneh-Arbib, A Shiferstein, N Dagan, S Fein, L Telem, E Muchtar, ... European journal of clinical microbiology & infectious diseases 32, 1511-1516, 2013 | 81 | 2013 |
| Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting M Mittelman, O Magen, N Barda, N Dagan, HS Oster, A Leader, R Balicer Blood, The Journal of the American Society of Hematology 139 (10), 1439-1451, 2022 | 67 | 2022 |
| Indirect protection of children from SARS-CoV-2 infection through parental vaccination S Hayek, G Shaham, Y Ben-Shlomo, E Kepten, N Dagan, D Nevo, ... Science 375 (6585), 1155-1159, 2022 | 55 | 2022 |
| Addressing bias in prediction models by improving subpopulation calibration N Barda, G Yona, GN Rothblum, P Greenland, M Leibowitz, R Balicer, ... Journal of the American Medical Informatics Association 28 (3), 549-558, 2021 | 55 | 2021 |
| BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply. N Barda, N Dagan, RD Balicer The New England Journal of Medicine 384 (20), 2021 | 49 | 2021 |
| Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex N Dagan, N Barda, RD Balicer New England Journal of Medicine 385 (24), 2299-2299, 2021 | 47 | 2021 |
| MHC haplotyping of SARS-CoV-2 patients: HLA subtypes are not associated with the presence and severity of COVID-19 in the Israeli population S Ben Shachar, N Barda, S Manor, S Israeli, N Dagan, S Carmi, R Balicer, ... Journal of Clinical Immunology 41 (6), 1154-1161, 2021 | 44 | 2021 |
